Revium Rx (RVRC) Price to Book (2024 - 2026)
Revium Rx's (RVRC) quarterly Price to Book came in at 18.38 in Q2 2026, up 1021.22% year-over-year from 1.64 in Q2 2025, and up 300.41% quarter-over-quarter from 4.59 in Q4 2025.
Analysis
Revium Rx (RVRC) Price to Book (2024 - 2026) Analysis & Trends
Revium Rx has disclosed Price to Book across 3 years of filings, most recently posting 18.38 for Q2 2026.
- In Q2 2026, Price to Book rose 1021.22% year-over-year to 18.38; the TTM figure through Jun 2026 stood at 18.38 (up 1021.22% YoY), while the FY2025 annual figure was 4.59, up 272.3% from the prior year.
- Price to Book came in at 18.38 for Q2 2026 at Revium Rx, up from 4.59 in the prior quarter.
- In the past five years, Price to Book ranged from a high of 18.38 in Q2 2026 to a low of 1.23 in Q4 2024.
- Average Price to Book over 3 years is 6.46, with a median of 3.11 recorded in 2025.
- Year-over-year, Price to Book jumped 272.3% in 2025 and soared 1021.22% in 2026.
- Over 3 years, Price to Book stood at 1.23 in 2024, then surged by 272.3% to 4.59 in 2025, then surged by 300.41% to 18.38 in 2026.
- Per Business Quant data, the three most recent Price to Book figures were 18.38 in Q2 2026, 4.59 in Q4 2025, and 1.64 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Revium Rx | 86.84 Mn | 85.34 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18.38 |
| Dec 31, 2025 | 4.59 |
| Jun 30, 2025 | 1.64 |
| Dec 31, 2024 | 1.23 |